Sorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Ups Its Stake and Reiterates Demands

A newly amended 13D filing with the US SEC revealed that Leonard A. Potter’s Wildcat Capital Management LLC has sent a new letter to the board of Sorrento Therapeutics Inc. (NASDAQ:SRNE) repeating their demands that the company terminate the pending Financing Transaction,  remove Dr. Ji as CEO of the company and to appoint three directors nominated by the Wildcat Shareholders. All these demands are for the objective of achieving the maximum shareholder value for stopping the completion of the value destroying sale of nearly half the equity in the company. Wildcat Capital Management LLC currently owns 2.8 million common shares of Sorrento Therapeutics (NASDAQ:SRNE), which account 7.0% of the company’s outstanding stock. This is a slight increase in the number of shares, compared to 2.6 million shares Wildcat Capital Management disclosed in a previous 13D filing, which accounted for 6.8% of the total amount of shares.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Sorrento Therapeutics (NASDAQ:SRNE) is a biopharmaceutical company with a main focus on discovering a variety of medical therapeutics that should answer many unresolved medical issues such as the treatment of chronic cancer pain, across the US, Europe and international markets. Year-to-date, Sorrento’s stock is down by 37.66%.  A month ago, FBR & Co. and Rodman & Renshaw cut their price targets to $16 and $30 from $21 and $40 respectively, but maintained their ‘Outperform’ and ‘Buy’ ratings on Sorrento’s stock.

The number of hedge fund long Sorrento Therapeutics (NASDAQ:SRNE) has decreased by two, and 11 hedge funds reported long positions in this stock at the end of December. Wildcat Capital Management held the largest position, followed by  Bihua Chen’s Cormorant Asset Management, with a stake worth around $18.3 million. Other investors that were bullish on this stock encompassed venBio Select Advisor, and Israel Englander’s Millennium Management.

Among the investors who sold off their positions in Sorrento Therapeutics (NASDAQ:SRNE) heading into 2016 are Hal Mintz’s Sabby Capital, which dropped an estimated $1.9 million in stock, and  D. E. Shaw’s D E Shaw, which dumped about $0.4 million worth.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Wildcat Capital Management 0 2,676,193 0 2,676,193 2,676,193 6.7%
Wildcat Liquid Alpha 0 184,000 0 184,000 184,000 0.5%
Infinity Q Capital Management 0 123,597 0 123,597 123,597 0.3%
Infinity Q Management Equity 0 123,597 0 123,597 123,597 0.3%
Infinity Q Diversified Alpha Fund 0 123,597 0 123,597 123,597 0.3%
Bonderman Family Limited Partnership 0 2,799,790 0 2,799,790 2,799,790 7.0%
Leonard A. Potter 0 2,799,790 0 2,799,790 2,799,790 7.0%
James Velissaris 0 123,597 0 123,597 123,597 0.3%

Follow Leonard A. Potter's Wildcat Capital Management

Page 1 of 15 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

(Amendment No. 3)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

Sorrento Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
83587F202
(CUSIP Number)

Leonard
A. Potter

President
and Managing Member

Wildcat
Capital Management, LLC

888
Seventh Avenue

New
York, NY 10106

(212)
468-5100

(Name,
Address and Telephone Number of Person

Authorized
to Receive Notices and Communications)

May 10, 2016
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐☐

Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 15 Pages)

______________________

* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 2 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 2 of 15 Pages
1

NAMES OF REPORTING PERSONS

Wildcat Capital Management, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

2,676,193 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

2,676,193 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

2,676,193 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

6.7% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock (as defined herein) outstanding as of May
3, 2016, as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the
Securities and Exchange Commission (the “SEC”) on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 3 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 3 of 15 Pages
1

NAMES OF REPORTING PERSONS

Wildcat – Liquid Alpha, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

WC (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

184,000 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

184,000 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

184,000 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.5% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 4 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 4 of 15 Pages
1

NAMES OF REPORTING PERSONS

Infinity Q Capital Management, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

123,597 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

123,597 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

123,597 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 5 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 5 of 15 Pages
1

NAMES OF REPORTING PERSONS

Infinity Q Management Equity, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

123,597 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

123,597 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

123,597 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 6 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 6 of 15 Pages
1

NAMES OF REPORTING PERSONS

Infinity Q Diversified Alpha Fund

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

WC (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

123,597 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

123,597 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

123,597 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 7 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 7 of 15 Pages
1

NAMES OF REPORTING PERSONS

Bonderman Family Limited Partnership

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

WC (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Texas

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

2,799,790 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

2,799,790 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

2,799,790 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

7.0% (See Item 5)*

14

TYPE OF REPORTING PERSON

PN

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 8 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 8 of 15 Pages
1

NAMES OF REPORTING PERSONS

Leonard A. Potter

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

2,799,790 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

2,799,790 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

2,799,790 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

7.0% (See Item 5)*

14

TYPE OF REPORTING PERSON

IN

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 9 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 9 of 15 Pages
1

NAMES OF REPORTING PERSONS

James Velissaris

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

123,597 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

123,597 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

123,597 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)*

14

TYPE OF REPORTING PERSON

IN

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 10 of 15 – SEC Filing

 

This Amendment No. 3 (the “Amendment”)
amends and supplements the Schedule 13D filed on April 18, 2016, as amended and supplemented by Amendment No. 1 filed on April
26, 2016 and Amendment No. 2 filed on May 6, 2016 (as so amended, the “Original Schedule 13D” and, as further
amended and supplemented by this Amendment, the “Schedule 13D”) by Wildcat Capital Management, LLC, Wildcat
– Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha
Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris with respect to the Common Stock of the Issuer.
Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original
Schedule 13D.

Item 4.  Purpose of Transaction

This Amendment amends and supplements Item 4
of the Original Schedule 13D by inserting the following after the fifth paragraph:

“On May 10, 2016, WLA and BFLP submitted
a letter (the “May 10 Letter”) to the Board reiterating their concerns and demands set forth in the May 5 Letter,
including (i) termination of the Transactions, (ii) termination of Dr. Ji as the CEO and (iii) appointment of three directors to
be nominated by WLA and BFLP to lead the Special Committee. The May 10 Letter highlighted WLA’s and BFLP’s concerns
regarding the Issuer’s press release of May 9, 2016 (the “May 9 Press Release”) announcing that the Issuer
had previously engaged financial advisors to assist the Issuer in exploring and evaluating strategic alternatives although such
engagement was not previously disclosed. The May 10 Letter further provided that the May 9 Press Release failed to address WLA’s
and BFLP’s concerns set forth in the May 5 Letter and restated WLA’s and BFLP’s intent to pursue their available
remedies, including, among other things, legal action on their own and/or the Issuer’s behalf. A copy of the May 10 Letter
is attached as Exhibit 5.”

Item 5. Interest in Securities of the Issuer

This
Amendment amends and restates the second, third and fourth paragraphs of Item 5 of the Original Schedule 13D in their entirety
as set forth below:

“(a)–(b) The following
disclosure assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, which is based on
information provided in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC
on May 10, 2016.

Pursuant to Rule 13d-3 of the Act, the
Reporting Persons may be deemed to beneficially own, in the aggregate, 2,799,790 shares of Common Stock, which constitutes approximately
7.0% of the outstanding Common Stock.

(c) Except as set forth in Schedule
II hereto, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, without independent verification,
any person named in Item 2 hereof, has effected any transaction in the Common Stock during the past 60 days.”

Item 7. Material to Be Filed as Exhibits

This
Amendment amends and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

1. Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.
2. Demand for Inspection of Books and Records, dated April 11, 2016.
3. Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25,
2016.
4. Letter to the Board of Directors of the Issuer, dated May 5, 2016.

Page 10 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 11 of 15 – SEC Filing

5. Letter to the Board of Directors of the Issuer, dated May 10, 2016.

Page 11 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 12 of 15 – SEC Filing

SIGNATURE

After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 11, 2016

Wildcat Capital Management, LLC

By:   /s/ Leonard A. Potter   

Name:  Leonard
A. Potter
Title: President 

 

Wildcat – Liquid Alpha, LLC

By:   /s/ Clive Bode           
Name:  Clive Bode
Title: President

Infinity Q Capital Management, LLC

By:   /s/ Leonard A. Potter   

Name:  Leonard
A. Potter
Title: Chief Executive Officer 

 

Infinity Q Management Equity, LLC

By:   /s/ James Velissaris           
Name: James Velissaris
Title: Sole Manager

Infinity Q Diversified Alpha Fund

By: Infinity Q Capital Management, LLC

By:   /s/ Leonard A. Potter   
Name:  Leonard A. Potter
Title: Chief Executive Officer

Page 12 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 13 of 15 – SEC Filing

Bonderman Family Limited Partnership

By:   /s/ Clive Bode  
Name: Clive Bode
Title: President

Leonard A. Potter

By:   /s/ Leonard A. Potter   
Name:  Leonard A. Potter

James Velissaris

By:   /s/ James Velissaris  
Name:  James Velissaris




Page 13 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 14 of 15 – SEC Filing

Schedule II

Reporting Person Buy (B) / Sell (S) Trade Date Type of Transaction Quantity Price per Share
Bonderman Family Limited Partnership B 05/06/2016 Open Market (NASDAQ) 74,537 $5.575
Bonderman Family Limited Partnership B 05/10/2016 Open Market (NASDAQ) 101,720 $5.638

Page 14 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 15 of 15 – SEC Filing

 

INDEX TO EXHIBITS

1. Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*
2. Demand for Inspection of Books and Records, dated April 11, 2016.**
3. Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25,
2016.***
4. Letter to the Board of Directors of the Issuer, dated May 5, 2016.****
5. Letter to the Board of Directors of the Issuer, dated May 10, 2016.

_________________

*Incorporated herein by reference
to the Agreement of Joint Filing by and among Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital
Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard
A. Potter and James Velissaris, dated as of April 18, 2016, which was previously filed with the SEC as Exhibit 1 to Schedule 13G
filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management
Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on
April 18, 2016.

**Incorporated herein by
reference to Demand for Inspection of Books and Records, dated April 11, 2016, which was previously filed with the SEC as Exhibit
2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC,
Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and
James Velissaris, on April 18, 2016.

***Incorporated herein by
reference to Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on
April 25, 2016, which was previously filed with the SEC as Exhibit 3 to Amendment No. 1 to Schedule 13D filed by Wildcat Capital
Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity
Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 26, 2016.

****Incorporated herein by
reference to Letter to the Board of Directors of the Issuer, dated May 5, 2016, which was previously filed with the SEC as Exhibit
4 to Amendment No. 2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital
Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard
A. Potter and James Velissaris, on May 6, 2016.

 

Page 15 of 15 Pages

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)